TY - JOUR
T1 - Immune Assessment Today
T2 - Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond
AU - Pandey, Surya
AU - Cholak, Meghan E.
AU - Yadali, Rishita
AU - Sosman, Jeffrey A.
AU - Tetreault, Marie-Pier
AU - Fang, Deyu
AU - Pollack, Seth Michaels
AU - Gnjatic, Sacha
AU - Obeng, Rebecca
AU - Lyerly, H. Kim
AU - Sonabend, Adam M.
AU - Guevara-Patiño, José A.
AU - Butterfield, Lisa H.
AU - Zhang, Bin
AU - Maecker, Holden T.
AU - Le Poole, I. Caroline
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/2
Y1 - 2024/2
N2 - As part of a symposium, current and former directors of Immune Monitoring cores and investigative oncologists presented insights into the past, present and future of immune assessment. Dr. Gnjatic presented a classification of immune monitoring technologies ranging from universally applicable to experimental protocols, while emphasizing the need for assay harmonization. Dr. Obeng discussed physiologic differences among CD8 T cells that align with anti-tumor responses. Dr. Lyerly presented the Soldano Ferrone lecture, commemorating the passionate tumor immunologist who inspired many, and covered a timeline of monitoring technology development and its importance to immuno-oncology. Dr. Sonabend presented recent achievements in glioblastoma treatment, accentuating the range of monitoring techniques that allowed him to refine patient selection for clinical trials. Dr. Guevara-Patiño focused on hypoxia within the tumor environment and stressed that T cell viability is not to be confused with functionality. Dr. Butterfield accentuated monitoring of dendritic cell metabolic (dys)function as a determinant for tumor vaccine success. Lectures were interspersed with select abstract presentations. To summarize the concepts, Dr. Maecker from Stanford led an informative forum discussion, pointing towards the future of immune monitoring. Immune monitoring continues to be a guiding light towards effective immunotherapeutic strategies.
AB - As part of a symposium, current and former directors of Immune Monitoring cores and investigative oncologists presented insights into the past, present and future of immune assessment. Dr. Gnjatic presented a classification of immune monitoring technologies ranging from universally applicable to experimental protocols, while emphasizing the need for assay harmonization. Dr. Obeng discussed physiologic differences among CD8 T cells that align with anti-tumor responses. Dr. Lyerly presented the Soldano Ferrone lecture, commemorating the passionate tumor immunologist who inspired many, and covered a timeline of monitoring technology development and its importance to immuno-oncology. Dr. Sonabend presented recent achievements in glioblastoma treatment, accentuating the range of monitoring techniques that allowed him to refine patient selection for clinical trials. Dr. Guevara-Patiño focused on hypoxia within the tumor environment and stressed that T cell viability is not to be confused with functionality. Dr. Butterfield accentuated monitoring of dendritic cell metabolic (dys)function as a determinant for tumor vaccine success. Lectures were interspersed with select abstract presentations. To summarize the concepts, Dr. Maecker from Stanford led an informative forum discussion, pointing towards the future of immune monitoring. Immune monitoring continues to be a guiding light towards effective immunotherapeutic strategies.
KW - biomarkers
KW - cancer therapy
KW - core facility
KW - immune cells
KW - immune monitoring
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85184930796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184930796&partnerID=8YFLogxK
U2 - 10.3390/cancers16030475
DO - 10.3390/cancers16030475
M3 - Article
C2 - 38339227
AN - SCOPUS:85184930796
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 3
M1 - 475
ER -
